Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
86.66
+0.77 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
56
57
Next >
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 02, 2024
From
AstraZeneca
Via
Business Wire
3 No-Brainer Stocks to Buy in June
June 02, 2024
Now is the time to invest in these great stocks.
Via
The Motley Fool
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
May 30, 2024
AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29, 2024
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.
Via
Benzinga
Exposures
Product Safety
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
May 22, 2024
Via
Benzinga
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
May 29, 2024
Both businesses have road maps for the future, but one is better.
Via
The Motley Fool
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
May 29, 2024
Its new strategic roadmap aims to catapult the company forward.
Via
The Motley Fool
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.
Via
Benzinga
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
May 27, 2024
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
Via
Benzinga
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
May 27, 2024
From
AstraZeneca
Via
Business Wire
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
May 23, 2024
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
May 23, 2024
From
AstraZeneca
Via
Business Wire
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
May 23, 2024
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later...
Via
Benzinga
The RBNZ Maintained Its Hawkish Bias, Leaving The Interest Rate At 5.5%
May 22, 2024
The Reserve Bank of New Zealand kept the official cash rate at 5.5% during its May 2024 policy meeting, extending the rate pause for the 7th straight time and confirming market expectations.
Via
Talk Markets
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
May 22, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
May 21, 2024
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new...
Via
Benzinga
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From
AstraZeneca
Via
Business Wire
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
May 20, 2024
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with...
Via
Benzinga
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
May 20, 2024
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
May 16, 2024
AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various...
Via
Benzinga
Exposures
COVID-19
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
May 16, 2024
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Blue-Chip Stocks to Protect Your Wealth as the Economy Slows
May 16, 2024
These are the low-beta blue-chip stocks to buy, as they represent fundamentally strong ideas with robust cash flow potential.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13, 2024
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.
Via
Benzinga
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
May 12, 2024
Johnson & Johnson isn't the ultra-safe stock it used to be.
Via
The Motley Fool
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
56
57
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.